Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company focused on the development of targeted therapies for a number of different cancers. Our mission is to extend the lives of cancer patients by developing potential first-in-class therapies and companion diagnostics. Celcuity's lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor Celcuity is conducting a Phase 3 registration-enabling ...
Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company focused on the development of targeted therapies for a number of different cancers. Our mission is to extend the lives of cancer patients by developing potential first-in-class therapies and companion diagnostics. Celcuity's lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor Celcuity is conducting a Phase 3 registration-enabling ...
